Federated Hermes Inc. Sells 282,160 Shares of DexCom, Inc. (NASDAQ:DXCM)

Federated Hermes Inc. cut its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 77.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 80,713 shares of the medical device company's stock after selling 282,160 shares during the period. Federated Hermes Inc.'s holdings in DexCom were worth $6,277,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Geode Capital Management LLC increased its position in shares of DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company's stock valued at $664,056,000 after purchasing an additional 214,136 shares during the period. Coldstream Capital Management Inc. grew its holdings in DexCom by 45.3% during the third quarter. Coldstream Capital Management Inc. now owns 11,253 shares of the medical device company's stock worth $781,000 after acquiring an additional 3,508 shares during the period. Toronto Dominion Bank raised its position in DexCom by 3.1% in the third quarter. Toronto Dominion Bank now owns 204,522 shares of the medical device company's stock worth $13,711,000 after acquiring an additional 6,227 shares in the last quarter. Virtu Financial LLC acquired a new stake in DexCom in the 3rd quarter valued at about $1,020,000. Finally, Pine Valley Investments Ltd Liability Co boosted its position in shares of DexCom by 59.2% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,679 shares of the medical device company's stock valued at $381,000 after purchasing an additional 2,111 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Morgan Stanley raised their price objective on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Mizuho assumed coverage on DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 target price on the stock. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and upped their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of "Moderate Buy" and a consensus target price of $99.00.

DexCom Stock Up 2.7 %

Shares of NASDAQ DXCM traded up $1.84 during mid-day trading on Tuesday, reaching $69.23. The company had a trading volume of 4,613,566 shares, compared to its average volume of 4,194,907. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $139.24. The stock's 50 day moving average is $76.49 and its 200-day moving average is $76.68. The stock has a market capitalization of $27.15 billion, a PE ratio of 48.41, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. The trade was a 8.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $914,940.00. Following the transaction, the executive vice president now directly owns 105,602 shares in the company, valued at $7,432,268.76. The trade was a 10.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock worth $8,044,178 over the last ninety days. 0.30% of the stock is currently owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.